Overview

Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus

Status:
Completed
Trial end date:
2000-10-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy and radiation therapy in treating patients with cancer of the esophagus.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Albumin-Bound Paclitaxel
Cisplatin
Paclitaxel
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed epidermoid carcinoma or adenocarcinoma of
the esophagus eligible for potentially curative radiotherapy Disease in one of the
following categories: Newly diagnosed Locoregional failure after prior resection with
curative intent Positive microscopic margin after palliative resection of all gross disease
Disease clinically limited to esophagus T 1-4, any N, M0 Gastroesophageal junction tumor
allowed No positive pleural, pericardial, or peritoneal cytology No tracheobronchial
invasion on bronchoscopy, including tracheoesophageal fistula

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100%
Hematopoietic: WBC more than 4,000/mm3 Platelet count at least 150,000/mm3 Hepatic:
Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 1.5 mg/dL OR
Creatinine clearance at least 65 mL/min per 1.73 square meters Cardiovascular: No NYHA
class 3/4 status No cerebral vascular disease No hypertension Other: No severe uncontrolled
diabetes No uncontrolled infection No other medical condition that precludes treatment No
mental status abnormality that precludes comprehension of or compliance with treatment No
active cancer arising at another primary site other than basal cell carcinoma of the skin
or in situ cervical carcinoma

PRIOR CONCURRENT THERAPY: No prior chemotherapy or radiotherapy